Mumbai: Molbio Diagnostics has announced an exclusive collaboration with Philadelphia-based UE LifeSciences to bring the iBreastExam device to global markets.
The partnership seeks to expand access to early breast cancer detection for millions of women across more than 50 countries, including India, Africa, the Middle East, CIS nations, the Philippines, Indonesia, and Vietnam.
iBreastExam to Address Gaps in Early Detection
Through this collaboration, Molbio Diagnostics will distribute UE LifeSciences’ iBreastExam, a painless, radiation-free, and FDA-cleared breast cancer screening device.
The initiative is focused on tackling late-stage detection, a leading contributor to preventable breast cancer mortality. Molbio will leverage its extensive healthcare distribution network to promote, market, and make the device available to both public and private healthcare providers across multiple geographies.
Also Read: Pune: First Jetstream Atherectomy at Ruby Hall Clinic Saves Woman from Amputation
About iBreastExam
The iBreastExam is a US FDA-cleared, ultra-portable, battery-operated point-of-care device that enables rapid breast cancer screening in primary healthcare settings and large-scale public health campaigns.
Using advanced sensor technology, the device automates and enhances the physical breast examination, helping primary care providers detect breast lumps in minutes without pain, radiation, or specialized infrastructure. Its ease of use, portability, and secure cloud storage for follow-up make it particularly effective in low-resource environments where access to mammograms is limited.
Mihir Shah, Founder and CEO of UE LifeSciences, emphasized, “Our collaboration with Molbio Diagnostics is an important step towards improving access to early breast health screening, particularly in areas where access remains a challenge. Molbio’s market reach and expertise can amplify our mission to transform women’s health and save lives through innovative early detection.”
Addressing Global Health Needs
Breast cancer continues to be the most prevalent cancer among women worldwide, contributing significantly to rising cancer incidence and mortality rates. By expanding the reach of iBreastExam, Molbio Diagnostics and UE LifeSciences aim to make early detection more equitable and accessible.
